Cynata Therapeutics Ltd represents values of innovation, collaboration, and dedication. With a strong corporate philosophy focused on developing novel stem cell therapies, Cynata is committed to improving patient outcomes and addressing unmet medical needs. As a leading biotechnology company, Cynata operates with a passion for scientific excellence and a drive to deliver transformative treatments. By harnessing the unique capabilities of its proprietary Cymerus™ technology, the company aims to revolutionize the field of regenerative medicine. Cynata Therapeutics Ltd prioritizes ethical practices, community engagement, and the pursuit of groundbreaking advancements to shape the future of healthcare.

Cynata Therapeutics Ltd is primarily present in Australia, where it is headquartered.

Cynata Therapeutics Ltd has achieved several significant milestones. Firstly, the company successfully developed and patented a game-changing Cymerus™ technology, which enables the production of high-quality mesenchymal stem cells. Additionally, they conducted successful preclinical trials, demonstrating the potential of Cymerus™ MSCs in various therapeutic applications. Cynata Therapeutics Ltd also achieved a major milestone by conducting the world's first clinical trial using an allogeneic mesenchymal stem cell product derived from a single induced pluripotent stem cell donor. Furthermore, the company secured collaboration and licensing agreements with renowned pharmaceutical companies, further validating their technology and expanding their reach in the global market.

Cynata Therapeutics Ltd is an Australian-based biotechnology company specializing in regenerative medicine. Established in 2011, the company focuses on developing innovative therapeutic stem cell products for a broad range of medical conditions. With a strong emphasis on clinical advancements, Cynata Therapeutics has made significant progress in stem cell research and development. Boasting a team of accomplished scientists and researchers, the company's revolutionary Cymerus™ platform technology allows for large-scale production of high-quality mesenchymal stem cells. Cynata Therapeutics is committed to transforming healthcare through their groundbreaking stem cell technology, offering hope for the treatment of various diseases and conditions.

The main competitors of Cynata Therapeutics Ltd in the market are Mesoblast Limited, Pluristem Therapeutics Inc., and Athersys Inc.

Cynata Therapeutics Ltd is primarily active in the biotechnology and pharmaceutical industries.

Cynata Therapeutics Ltd is a biotechnology company with a unique business model focused on regenerative medicine. The company specializes in the development and commercialization of a proprietary stem cell technology known as Cymerus™. This technology enables large-scale production of high-quality mesenchymal stem cells (MSCs) from a single donor, eliminating the need for multiple donors. Cynata Therapeutics aims to utilize this technology to address a wide range of therapeutic applications, including graft-versus-host disease, cardiovascular diseases, osteoarthritis, and respiratory disorders. By leveraging their innovative Cymerus™ platform, Cynata Therapeutics strives to revolutionize the way regenerative medicine is approached and provide effective treatments for various medical conditions.

P/E odnos Cynata Therapeutics iznosi -4,24.

KUV kompanije Cynata Therapeutics iznosi 98,91.

AlleAktien kvalitativni skor za Cynata Therapeutics je 5/10.

Cynata Therapeutics promet je 417.710,00 AUD.

Dobit Cynata Therapeutics je -9,74 mil. AUD.

Cynata Therapeutics Ltd is an Australian biotechnology company specializing in the development of cellular therapies for the treatment of various diseases. The company's business model is based on the use of its proprietary mesenchymal stem cell technology, which enables a wide range of potential applications. Cynata Therapeutics has divisions focusing on regenerative medicine, specifically therapies for tissue regeneration after injuries or diseases, and immunotherapy, aiming to improve the body's immune system for more effective cancer and disease treatment. The company also offers various products based on its mesenchymal stem cell technology for research and development in cell-based therapies. Cynata Therapeutics operates through innovation, research, and development, continually investing in its scientists and research partners to improve its technology and discover new applications. Additionally, it collaborates with leading researchers and institutions to share findings and promote therapy development. The company also pursues international cooperation and partnerships to market and utilize its technology and products globally, recently partnering with Fujifilm for distribution in Japan and other Asian markets. In summary, Cynata Therapeutics provides a wide range of cellular therapies and products based on its mesenchymal stem cell technology, aiming to improve patient care and offer solutions for serious and life-threatening diseases. With its strong research efforts and international focus, the company will continue to play a leading role in the cellular therapy market and establish itself in the field of regenerative medicine and immunotherapy.

Cynata Therapeutics isplaćuje dividendu od 0 AUD raspoređenu preko isplata u toku godine.

Dividenda za Cynata Therapeutics trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Cynata Therapeutics je AU000000CYP7.

WKN od Cynata Therapeutics je A1W8VE.

Oznaka za praćenje akcija kompanije Cynata Therapeutics je CYP.AX.

U poslednjih 12 meseci, Cynata Therapeutics je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Cynata Therapeutics će verovatno isplatiti dividendu od 0 AUD.

Dividendski prinos od Cynata Therapeutics trenutno iznosi .

Cynata Therapeutics isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Cynata Therapeutics je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 AUD. To odgovara dividendnom prinosu od 0 %.

Cynata Therapeutics se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Cynata Therapeutics od 1. 11. 2024. u iznosu od 0 AUD, morali ste da imate akciju u depou pre Ex-dana 1. 11. 2024..

Isplata poslednje dividende izvršena je 1. 11. 2024..

U godini 2023 kompanija Cynata Therapeutics je isplatila 0 AUD kao dividende.

Dividende od Cynata Therapeutics se isplaćuju u AUD.